⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

Evaluating the Safety, Tolerability, and Pharmacokinetics of QRL-101 in Two Phase 1 Studies: QRL-101-01 in Healthy Adults and QRL-101-02 in Adults with ALS (P6-11.019)

Angela Genge Bryan Boggs Rakhee Ganti Sandy Hinckley Kristina Johnson John Polzer Samantha Rubino Kristiana Salmon Daniel Elbaum

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Evaluate the safety, tolerability, and pharmacokinetics of QRL-101 in healthy volunteers and people living with ALS.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Genge et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcc5b6db643587677386 https://doi.org/10.1212/wnl.0000000000205294

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1QRL-201-01—A Multi-center, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis (P6-11.010)2024 · 3 citations
2Clinical Progress Update From PRO-101, a Hybrid Phase One Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Prosetin in Participants With ALS (P10-9.007)Human Clinical Trial · 2026
3QLS4131, a next-generation GPRC5D×BCMA×CD3 trispecific T-cell engager, in patients with relapsed/refractory multiple myeloma (RRMM): Initial results of a first-in-human Phase Ⅰa study2025 · 3 citations
4The Small Molecule VQ-101 Demonstrates Sustained Lysosomal Glucocerebrosidase (GCase) Activation in Idiopathic Parkinson’s Disease (S26.005)Original Research · 2026
5Safety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Doses of a Next Generation Prodrug Troriluzole in Healthy Subjects (P4-4.012)2024
6Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after <sup>177</sup>Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.2024 · 8 citations
7A novel and selective oral PI3Kα/δ inhibitor, TQ-B3525, in patients with relapsed and/or refractory follicular lymphoma: A phase II, single-arm, open-label study.2024
8A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma.2024 · 2 citations
9Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathologyNeurology · 2016
10Occupational Exposure to Petroleum-Derived Lubricants and Risk of Multiple SclerosisNeurology · 2026

More from Neurology